Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

Live Events
Sign Up / Login

Live Events
Sign Up / Login

Plus Library

By pinki@katapult.biz / February 13, 2025

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 1,426 - 1,450 of 2,875

«
1
…
56
57
58
59
60
…
115
»

State of the Art Radiation in NSCLC

State of the Art Radiation in NSCLC

Ana Botero, MD

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

Ana Velazquez Manana, MD, MSc

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

Ana Velazquez Manana, MD, MSc

Small Cell Lung Cancer: 1L and Beyond

Small Cell Lung Cancer: 1L and Beyond

Anne Chiang, MD

Small Cell Lung Cancer: 1L and Beyond

Small Cell Lung Cancer: 1L and Beyond

Anne Chiang, MD

Small Cell Lung Cancer: Targeting This Difficult Target

Small Cell Lung Cancer: Targeting This Difficult Target

Anne Chiang, MD, PhD

Small Cell Lung Cancer: Targeting This Difficult Target

Small Cell Lung Cancer: Targeting This Difficult Target

Anne Chiang, MD, PhD

Squamous Cell Carcinoma of the Lung: Finally Some Progress

Squamous Cell Carcinoma of the Lung: Finally Some Progress

Antoinette J Wozniak - MD - FASCO - FACP

Neuroendocrine Tumors of the Lung "A Spectrum of Clinical Challenges"

Neuroendocrine Tumors of the Lung "A Spectrum of Clinical Challenges"

Antoinette J Wozniak, MD, FACP, FASCO

Squamous Cell Carcinoma

Squamous Cell Carcinoma

Antoinette J. Wozniak, MD, FACP, FASCO

Neuroendocrine Tumors of the Lung "A Spectrum of Clinical Challenges"

Neuroendocrine Tumors of the Lung "A Spectrum of Clinical Challenges"

Antoinette J. Wozniak, MD, FACP, FASCO

The Role of Stereotactic Body Radiation Therapy (SBRT) in Lung Cancer

The Role of Stereotactic Body Radiation Therapy (SBRT) in Lung Cancer

Arya Amini, MD

Immunotherapy in NSCLC: First Line for Advanced Disease

Immunotherapy in NSCLC: First Line for Advanced Disease

Balazs Halmos, MD, MS

Immunotherapy in NSCLC: First Line for Advanced Disease

Immunotherapy in NSCLC: First Line for Advanced Disease

Balazs Halmos, MD, MS

Clinical Utility and Future indications of Liquid Biopsies in Lung Cancer

Clinical Utility and Future indications of Liquid Biopsies in Lung Cancer

Benjamin Levy, MD

Clinical Utility and Future indications of Liquid Biopsies in Lung Cancer

Clinical Utility and Future indications of Liquid Biopsies in Lung Cancer

Benjamin Levy, MD

Radiation in Early-Stage NSCLC

Radiation in Early-Stage NSCLC

Billy W. Loo, Jr., MD, PhD, FASTRO, FACR

Radiation in Early-Stage NSCLC

Radiation in Early-Stage NSCLC

Billy W. Loo, Jr., MD, PhD, FASTRO, FACR

Optimizing radiation in primary lung malignancies

Optimizing radiation in primary lung malignancies

Brian Lally, MD

ctDNA in Lung Cancer: Current State and Future Perspectives

ctDNA in Lung Cancer: Current State and Future Perspectives

Bruna Pellini, MD

ctDNA in Lung Cancer: Current State and Future Perspectives

ctDNA in Lung Cancer: Current State and Future Perspectives

Bruna Pellini, MD

Targeted Therapy in NSCLC

Targeted Therapy in NSCLC

Bruna Pellini, MD

Targeted Therapy in NSCLC

Targeted Therapy in NSCLC

Bruna Pellini, MD

PARP Inhibitors in SCLC

PARP Inhibitors in SCLC

Charles Rudin, MD, PhD

Optimal Management of Extensive SCLC (1st and 2nd Line)

Optimal Management of Extensive SCLC (1st and 2nd Line)

Charles Rudin, MD, PhD

«
1
…
56
57
58
59
60
…
115
»

Post navigation

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok